Amphastar seeks to develop product candidates in large markets with high technical barriers to entry that leverage our skills and competitive advantages within eight (8) technological platforms.
2.Immunogenicity for complex molecules;
4.Complex medications made from living cells and organisms:Peptide/proteins / rDNA;
5.Particle Engineering from nm to µm;
6.Interchangeable Biosimilar Insulins;
7.Combination products and innovative drug delivery systems; and
Amphastar will continue its focus on developing:
•Difficult to produce products, such as emulsions and suspensions;
•Generic products with a significant market but with no available API;
•New products with a unique marketing niche; and
•New delivery systems for well-established products.
Some of the products Amphastar has chosen to develop are on the FDA’s shortage list or are products that have been off patent but have not been pursued by other companies because they are technically challenging to develop or manufacture.
For more information on our pipeline, please refer to our corporate presentation under the "News and Events" section of our Investors tab.